Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Amyotrophic lateral sclerosis
(
ALS
) is the most common, progressive motor neurone disease but is rare in the obstetric population. Only 4 cases have been described in the English literature since 1975. We describe a 29 year old woman who presented with ataxia, lower limb weakness and dysarthria 4 weeks after the birth of her first child. The symptoms had onset during the pregnancy but had not been considered remarkable. There were clinical features of upper and lower motor neurone involvement without any sensory loss. MRI of brain and spine was normal.
CSF
analysis was negative. EMG studies confirmed the presence of widespread anterior horn cell dysfunction compatible with
ALS
. The patient was commenced on Riluzole and has progressed clinically, at 12 months post diagnosis.
...
PMID:Amyotrophic lateral sclerosis associated with pregnancy. 1179 21
Levels of the potent pro-inflammatory prostaglandin E(2) (PGE(2)) are elevated in postmortem spinal cords from patients with
ALS
, and inhibition of a key PGE(2)-synthesizing enzyme, cylcooxygenase-2, is neuroprotective in an in vitro model of
ALS
. The authors report that 82% of the patients with
ALS
studied had 2 to 10 times higher PGE(2) levels in
CSF
compared with normal control subjects. That affected areas of the CNS are inflamed in
ALS
supports this.
CSF
PGE(2) measurement may be useful in monitoring treatment for
ALS
.
...
PMID:Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. 1197 Oct 99
Pigment epithelium-derived factor (PEDF), a recently defined retinal trophic factor and anti-angiogenic factor for the eye, is also present in the CNS and is a motor neuron protectant. We asked whether PEDF levels in
CSF
are altered in patients with
amyotrophic lateral sclerosis
(
ALS
). Pigment epithelium-derived factor protein was detected by quantitative western blot analysis with a PEDF-specific antiserum. Levels of PEDF in
CSF
, expressed as a ratio to total
CSF
protein, were significantly elevated 3.4-fold in 15 patients with
ALS
compared with neurologic disease controls (p < 0.0003). This increase does not seem likely to reflect up-regulation of PEDF synthesis in muscle in response to denervation, as
CSF
PEDF was not elevated in severe denervating diseases other than
ALS
. Nor does the increase represent some non-specific release in neurodegeneration, as
CSF
PEDF was not elevated in other neurodegenerative diseases. While the mechanism of this presumably reactive increase is not known, the distinctive, surprisingly elevated level of PEDF in the
CSF
may be an autoprotective reaction in
ALS
.
...
PMID:Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. 1206 31
Observations of elevated
CSF
glutamate in
amyotrophic lateral sclerosis
(
ALS
), together with findings that motor neurons are selectively vulnerable to glutamate receptor-mediated ("excitotoxic") injury, support an excitotoxic contribution to the motor neuron loss in the disease. However, the basis of the apparent loss of astrocytic glutamate transport capacity in affected areas of motor cortex and spinal cord, which probably underlies the extracellular glutamate elevations, is unexplained. Here, we find that glutamate induces far greater reactive oxygen species (ROS) generation in cultured motor neurons than in other spinal neurons. In addition, we found that the ROS seem to be able to leave the motor neurons and induce oxidation and disruption of glutamate uptake in neighboring astrocytes. Correspondingly, in a transgenic mouse model of
ALS
, protein oxidation was increased in regions immediately surrounding motor neurons. These results provide a mechanism that can account for the localized loss of glial glutamate transport seen in the disease. Furthermore, the observations lend support for a feedforward model involving reciprocal interactions between motor neurons and glia, which may prove useful in understanding
ALS
pathogenesis.
...
PMID:Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. 1268 48
Nitration of tyrosine in biological conditions represents a pathological event that is associated with several neurodegenerative diseases, such as
amyotrophic lateral sclerosis
, Parkinson's disease and Alzheimer's disease (AD). Increased levels of nitrated proteins have been reported in AD brain and
CSF
, demonstrating the potential involvement of reactive nitrogen species (RNS) in neurodegeneration associated with this disease. Reaction of NO with O2- leads to formation of peroxynitrite ONOO-, which following protonation, generates cytotoxic species that oxidize and nitrate proteins. Several findings suggest an important role of protein nitration in modulating the activity of key enzymes in neurodegenerative disorders, although extensive studies on specific targets of protein nitration in disease are still missing. The present investigation represents a further step in understanding the relationship between oxidative modification of protein and neuronal death in AD. We previously applied a proteomics approach to determine specific targets of protein oxidation in AD brain, by successfully coupling immunochemical detection of protein carbonyls with two-dimensional polyacrylamide gel electrophoresis and mass spectrometry analysis. In the present study, we extend our investigation of protein oxidative modification in AD brain to targets of protein nitration. The identification of six targets of protein nitration in AD brain provides evidence to the importance of oxidative stress in the progression of this dementing disease and potentially establishes a link between RNS-related protein modification and neurodegeneration.
...
PMID:Proteomic identification of nitrated proteins in Alzheimer's disease brain. 1278 59
Neurofilaments (Nf) are the major constitutents of the axoskeleton and body fluid Nf levels are an important tool for estimating axonal degeneration in vivo. This paper presents a new sandwich ELISA allowing quantification of the NfH(SMI35) phosphoform from
CSF
, brain tissue and cell culture homogenates. The sensitivity of the NfH(SMI35) ELISA is 0.2 ng/ml with a recovery of 119% and a mean within- and between-batch precision of 10.6% and 23%, respectively.
CSF
NfH(SMI35) was stable at 4 degrees C, is not influenced by freeze-thaw cycles, and proteolysis present at room temperature could be prevented by adding protease inhibitors. Aggregate formation was observed for HPLC-purified bovine NfH and could be resolved by sonication. The upper reference value for
CSF
NfH(SMI35) levels (0.73 ng/ml) was defined as the 95% cumulative frequency from 416
CSF
samples. Based on this cutoff, a significantly higher proportion of patients with
amyotrophic lateral sclerosis
, space-occupying lesions, disc prolapse and subarachnoid haemorrhage had pathologically elevated NfH(SMI35) levels compared to patients with cluster headache or demyelinating disease.A new nomenclature is proposed to facilitate the comparison between ELISA, immunoblotting and immunocytochemistry.
...
PMID:A specific ELISA for measuring neurofilament heavy chain phosphoforms. 1295 6
Lack of growth factors and hypoxia are two recent hypotheses about mechanisms underlying motor neuron death in
amyotrophic lateral sclerosis
. With this background, serum from 15 patients with
amyotrophic lateral sclerosis
and 15 controls, and
CSF
from 15 patients and 10 controls were analysed for fibroblast growth factor 2 (FGF-2) using an immunoassay. Serum FGF-2 levels were higher in the patient group than in the control group. FGF-2 was detected in
CSF
in 11/15 patients, but in none of the 10 control subjects. There were no correlations between age, duration of disease or clinical rating and FGF-2 levels. The findings indicate that FGF-2 is involved in the pathophysiological chain of events in this disorder.
...
PMID:Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis. 1453 37
Dendritic cells are potent antigen-presenting cells that initiate and amplify immune responses. To determine whether dendritic cells participate in inflammatory reactions in
amyotrophic lateral sclerosis
(
ALS
), we examined mRNA expression of dendritic cell surface markers in individual sporadic
ALS
(sALS), familial
ALS
(fALS), and nonneurological disease control (NNDC) spinal cord tissues using semiquantitative and real-time reverse transcription polymerase chain reaction (RT-PCR). Immature (DEC205, CD1a) and activated/mature (CD83, CD40) dendritic cell transcripts were significantly elevated in
ALS
tissues. The presence of immature and activated/mature dendritic cells (CD1a(+) and CD83(+)) was confirmed immunohistochemically in
ALS
ventral horn and corticospinal tracts. Monocytic/macrophage/microglial transcripts (CD14, CD18, SR-A, CD68) were increased in
ALS
spinal cord, and activated CD68(+) cells were demonstrated in close proximity to motor neurons. mRNA expressions of the chemokine MCP-1, which attracts monocytes and myeloid dendritic cells, and of the cytokine macrophage-colony stimulating factor (M-CSF) were increased in
ALS
tissues. The MCP-1 protein was expressed in glia in
ALS
but not in control tissues and was increased in the
CSF
of
ALS
patients. Those patients who progressed most rapidly expressed significantly more dendritic transcripts than patients who progressed more slowly. These results support the involvement of immune/inflammatory responses in amplifying motor neuron degeneration in
ALS
.
...
PMID:Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. 1475 26
Deletion of the hypoxia-response element in the vascular endothelial growth factor (VEGF) promoter causes motor neuron degeneration in a mouse model. "At-risk" haplotypes with low circulating VEGF levels have been demonstrated in humans. Here the authors report low VEGF levels in the
CSF
of
ALS
patients during their first year of the disease, independently of VEGF promoter polymorphism. This finding early in
ALS
patients suggests a possible role for VEGF gene regulation in the pathogenesis of
ALS
.
...
PMID:Low levels of the vascular endothelial growth factor in CSF from early ALS patients. 1518 33
Since the proposal that excessive glutamatergic stimulation could be responsible for neuronal suffering and death, excitotoxicity and glutamate uptake deficits have been repeatedly confirmed to play a key role in the pathogenesis of different neurological diseases. Therefore, it is conceivable that assessing the glutamatergic system function directly in patients could be extremely useful for early diagnosis, prognostic evaluation, and optimization of the therapy. A possibility is offered by assessing glutamate levels in biological fluid, such as plasma and
CSF
, where increased levels of this amino acid have been reported in patients affected by stroke,
amyotrophic lateral sclerosis
(
ALS
), and AIDS dementia complex. However, the metabolic role of this amino acid acts as a confounding factor, and the possibility of directly assessing glutamatergic functional parameters, such as amino acid reuptake, would probably mirror closely the actual excitotoxic damage operative in each patient. Here we will describe our findings obtained in peripheral ex vivo cells, such as platelets and fibroblasts, both displaying a functional glutamate reuptake system. Consistent with a systemic-impairment assumption, glutamate uptake was shown to be reduced in peripheral cells of Alzheimer's disease, Down syndrome, Parkinson's disease,
ALS
, and stroke patients. Different systemic factors might be responsible for this phenomenon, including genetic predisposition, oxidative stress, and inflammatory response, raising new, exciting questions about the relevance of their possible interactions for the pathogenesis of neurological disorders.
...
PMID:Peripheral markers of glutamatergic dysfunction in neurological diseases: focus on ex vivo tools. 1558 9
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>